Meropenem ROTAC for CDK6 The inhibitory effect of Ikarisoside

The inhibitory effect of Ikarisoside A resulted in decrease of osteoclast-specific genes like matrix metalloproteinase 9 (MMP9)

InChiKey: XGDUNTSTRCLVLN-UHFFFAOYSA-N

8-diazaspiro[4

infected treated orally with PZQ (1

Meropenem ROTAC for CDK6 The inhibitory effect of IkarisosideMeropenem is an ultra broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Zwipen (India, Marketed by Nucleus) Mepem